Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock has declined 32% over the past three months.

In 2021, Regeneron reported total revenue of $16.1 billion, representing an increase of 89% compared to the previous fiscal year. That's a rare performance for the biotech giant.

In 2021, Regeneron reported total revenue of $16.1 billion, representing an increase of 89% compared to the previous fiscal year. That's a rare performance for the biotech giant.

Regeneron Pharmaceuticals’ stock price increased from $376 per share at the end of 2017 to about $585 currently, a substantial increase of about 56%.